Enabling Biogenerics: Exploiting Comparability to Limit Clinical Trial Needs

Published by: IDC

Published: Oct. 23, 2006 - 4 Pages

Table of Contents

Abstract

This Health Industry Insights Perspective describes analyst perspectives in response to recently proposed legislation to enable the approval of generic biological drugs (biogenerics) by the U.S. Food and Drug Administration (FDA). The proposed legislation aspires to provide competitive pressure to develop generic alternatives to FDA-approved biological drugs that have exhausted patent protections with the overall goal of decreasing drug costs for consumers.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.